News
Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced ...
A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting ...
New research from the University of Pittsburgh School of Medicine and La Jolla Institute for Immunology, published today in ...
As respiratory illnesses like COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the need for safe, ...
Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and ...
12d
Clinical Trials Arena on MSNCidara reports outcomes from trial of CD388 for preventing seasonal influenzaCidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational drug-Fc conjugate (DFC), CD388, for seasonal influenza prevention in healthy ...
Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current ...
12d
Asianet Newsable on MSNCidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share OfferingShares of Cidada Therapeutics doubled in value on Monday and jumped in after-hours trading as the biotech firm released ...
Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results